Home / Market News / $CRMD

$CRMD news and market catalysts

The 19 most recent market catalysts affecting $CRMD, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

19 catalysts 7 high impact 9 bullish 3 bearish Pharmaceuticals
Nov 16, 2026 Corporate Catalyst Neutral Impact 55
CorMedix Insider Acquires Shares
A CorMedix insider acquired $390,000 in company shares, indicating a vote of confidence from within the organization. Such insider buying can be a bullish signal for investors, as …
Nov 14, 2026 Corporate Catalyst Bullish Impact 90
CorMedix Completes Acquisition of Heron Therapeutics
CorMedix has finalized its acquisition of Heron Therapeutics, a significant corporate action. This event is material because Oppenheimer analysts have already highlighted it as a s…
Nov 12, 2026 Corporate Catalyst Bearish Impact 85
CorMedix Reports Third Quarter 2026 Financial Results and Provides Business Update
CorMedix announced third-quarter 2026 financial results, reporting revenue of $54.5 million, which surpassed analyst expectations. Despite the revenue beat, the company posted a ne…
Nov 10, 2026 Corporate Catalyst Bullish Impact 65
RBC Capital Markets Raises Price Target on CorMedix
RBC Capital Markets raised its price target on CorMedix Inc. shares from $14 to $15, maintaining an Outperform rating. This decision directly stems from CorMedix's recent acquisiti…
Nov 10, 2026 Corporate Catalyst Bullish Impact 85
Carlsmed Reports Third Quarter 2026 Financial Results and Raises Full-Year Guidance
Carlsmed announced robust third-quarter 2026 financial results, with a 65% revenue increase attributed to successful strategy execution and an expanding surgeon user base for its A…
Nov 9, 2026 Corporate Catalyst Bullish Impact 95
CorMedix Therapeutics to Acquire Substantially All Assets of Heron Therapeutics
CorMedix Therapeutics is acquiring substantially all assets of Heron Therapeutics in a deal valued at $145 million in cash, 14,583,333 shares of CorMedix common stock, and up to $5…
Nov 9, 2026 Corporate Catalyst Neutral Impact 95
Moelis & Company LLC Advises CorMedix on Asset Purchase Agreement
CorMedix Therapeutics has entered into a definitive asset purchase agreement to acquire substantially all assets of Heron Therapeutics for $145 million in cash. This is a major cor…
Nov 5, 2026 Corporate Catalyst Neutral Impact 55
CorMedix Inc. Schedules Third Quarter 2026 Earnings Announcement
CorMedix Inc. has scheduled its Q3 2026 earnings announcement for November 11, 2026, at 7:00 AM ET. This is a standard corporate disclosure, signaling an upcoming event that will p…
Nov 3, 2026 Corporate Catalyst Bullish Impact 60
Needham Maintains Buy Rating on CorMedix, Lowers Price Target
Needham analyst Serge Belanger maintained a 'Buy' rating on CorMedix, indicating continued positive sentiment towards the company. However, the price target was lowered from $15 to…
Nov 2, 2026 Corporate Catalyst Neutral Impact 65
CorMedix Therapeutics Provides Business Update and Reaffirms 2026 Revenue Guidance
CorMedix Therapeutics provided a business update, reaffirming its full-year 2026 revenue guidance and disclosing a strong cash position. This matters because maintaining guidance, …
Oct 30, 2026 Corporate Catalyst Bearish Impact 90
CorMedix Shares Decline Following DaVita Commentary on DefenCath Reimbursement
DaVita's CFO, Joel Ackerman, disclosed during their Q3 earnings call that Medicare add-on payments for CorMedix's DefenCath are projected to significantly decrease from Q1 to Q2 20…
Sep 23, 2026 Corporate Catalyst Neutral Impact 65
Oppenheimer Initiates Coverage On Cormedix with Outperform Rating, Announces Price Target of $15
Oppenheimer's initiation of coverage on Cormedix with an Outperform rating and a $15 price target is a positive development for the company. Analyst coverage can increase visibilit…
Sep 8, 2026 Corporate Catalyst Neutral Impact 55
Carlsmed Announces Promotion Of Jeff Bertolini To COO, Effective Immediately
The promotion of a COO is a positive internal development for Carlmed, indicating a focus on operational excellence and potentially smoother execution of strategic initiatives. Whi…
Aug 14, 2026 Corporate Catalyst Bullish Impact 55
RBC Capital Maintains Outperform on Cormedix, Raises Price Target to $14
RBC Capital analyst Leonid Timashev has maintained an Outperform rating on Cormedix and raised the price target from $13 to $14. This action signals continued confidence from a pro…
Aug 13, 2026 Corporate Catalyst Bullish Impact 85
CorMedix Stock Jumps on Strong DefenCath Sales
CorMedix Inc. announced impressive second-quarter results, with adjusted earnings and revenue surpassing consensus estimates. The significant driver of this performance was the str…
Aug 13, 2026 Corporate Catalyst Bullish Impact 75
CorMedix shares are trading higher after the company reported better-than-expected Q2 financial results.
This headline represents a significant corporate catalyst for CorMedix. Better-than-expected financial results directly impact investor perception of a company's health and future …
Aug 13, 2026 Corporate Catalyst Bullish Impact 75
Cormedix Q2 EPS $0.29 Beats $0.25 Estimate, Sales $101.931M Beat $95.621M Estimate
This headline is a significant corporate catalyst for Cormedix (CRMD). Beating both EPS and sales estimates suggests strong underlying business performance, potentially driven by s…
Aug 13, 2026 Corporate Catalyst Bearish Impact 55
Cormedix Affirms FY2026 Sales Guidance of $325.000M-$345.000M vs $334.089M Est
Cormedix (CRMD) filed an 8-K to affirm its fiscal year 2026 sales guidance, keeping the range at $325 million to $345 million. This filing essentially communicates that the company…
Aug 7, 2026 Corporate Catalyst Neutral Impact 55
U.S. District Court Granted Preliminary Approval Of CorMedix Derivative Settlement On July 24; Final Hearing Set For September 23
CorMedix announced that a U.S. District Court has granted preliminary approval for a derivative settlement. This is a positive step towards resolving a legal issue that likely invo…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.